Report cover image

Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 194 Pages
SKU # APRC20277717

Description

Summary

According to APO Research, The global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) include Sino Biopharmaceutical, Chia Tai Tianqing Pharmaceutical, Simcere Pharmaceutical, Qilu Pharmaceutical, Zydus, Pfizer, Natco Pharma, Hetero and Cipla, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs), also provides the sales of main regions and countries. Of the upcoming market potential for Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) sales, projected growth trends, production technology, application and end-user industry.

Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Segment by Company

Sino Biopharmaceutical
Chia Tai Tianqing Pharmaceutical
Simcere Pharmaceutical
Qilu Pharmaceutical
Zydus
Pfizer
Natco Pharma
Hetero
Cipla
Bristol Myers Squibb
AbbVie
Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Segment by Type

Ozanimod
Tofacitinib
Upadacitinib
Other
Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Segment by Application

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Market Size, 2020 VS 2024 VS 2031
1.3 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Market Size Estimates and Forecasts (2020-2031)
1.4 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales Estimates and Forecasts (2020-2031)
1.5 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Market Dynamics
2.1 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Industry Trends
2.2 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Industry Drivers
2.3 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Industry Opportunities and Challenges
2.4 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Industry Restraints
3 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Market by Manufacturers
3.1 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Manufacturers (2020-2025)
3.2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Manufacturers (2020-2025)
3.3 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Average Sales Price by Manufacturers (2020-2025)
3.4 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Manufacturers, Product Type & Application
3.7 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Market CR5 and HHI
3.8.2 Global Top 5 and 10 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Players Market Share by Revenue in 2024
3.8.3 2024 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Tier 1, Tier 2, and Tier 3
4 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Market by Type
4.1 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Type Introduction
4.1.1 Ozanimod
4.1.2 Tofacitinib
4.1.3 Upadacitinib
4.1.4 Other
4.2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Type
4.2.1 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Type (2020-2031)
4.2.3 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales Market Share by Type (2020-2031)
4.3 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Type
4.3.1 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Type (2020-2031)
4.3.3 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue Market Share by Type (2020-2031)
5 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Market by Application
5.1 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Application Introduction
5.1.1 Hospital Pharmacy
5.1.2 Online Pharmacy
5.1.3 Retail Pharmacy
5.2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Application
5.2.1 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Application (2020-2031)
5.2.3 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales Market Share by Application (2020-2031)
5.3 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Application
5.3.1 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Application (2020-2031)
5.3.3 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue Market Share by Application (2020-2031)
6 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Region
6.1 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Region (2020-2031)
6.2.1 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Region (2020-2025)
6.2.2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Region
7.1 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Region
7.1.1 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Region (2020-2025)
7.1.3 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue by Region (2026-2031)
7.1.4 Global Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue (2020-2031)
7.2.2 North America Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue (2020-2031)
7.3.2 Europe Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue (2020-2031)
7.4.2 Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Sino Biopharmaceutical
8.1.1 Sino Biopharmaceutical Comapny Information
8.1.2 Sino Biopharmaceutical Business Overview
8.1.3 Sino Biopharmaceutical Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Sino Biopharmaceutical Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Product Portfolio
8.1.5 Sino Biopharmaceutical Recent Developments
8.2 Chia Tai Tianqing Pharmaceutical
8.2.1 Chia Tai Tianqing Pharmaceutical Comapny Information
8.2.2 Chia Tai Tianqing Pharmaceutical Business Overview
8.2.3 Chia Tai Tianqing Pharmaceutical Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Chia Tai Tianqing Pharmaceutical Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Product Portfolio
8.2.5 Chia Tai Tianqing Pharmaceutical Recent Developments
8.3 Simcere Pharmaceutical
8.3.1 Simcere Pharmaceutical Comapny Information
8.3.2 Simcere Pharmaceutical Business Overview
8.3.3 Simcere Pharmaceutical Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Simcere Pharmaceutical Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Product Portfolio
8.3.5 Simcere Pharmaceutical Recent Developments
8.4 Qilu Pharmaceutical
8.4.1 Qilu Pharmaceutical Comapny Information
8.4.2 Qilu Pharmaceutical Business Overview
8.4.3 Qilu Pharmaceutical Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Qilu Pharmaceutical Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Product Portfolio
8.4.5 Qilu Pharmaceutical Recent Developments
8.5 Zydus
8.5.1 Zydus Comapny Information
8.5.2 Zydus Business Overview
8.5.3 Zydus Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Zydus Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Product Portfolio
8.5.5 Zydus Recent Developments
8.6 Pfizer
8.6.1 Pfizer Comapny Information
8.6.2 Pfizer Business Overview
8.6.3 Pfizer Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Pfizer Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Product Portfolio
8.6.5 Pfizer Recent Developments
8.7 Natco Pharma
8.7.1 Natco Pharma Comapny Information
8.7.2 Natco Pharma Business Overview
8.7.3 Natco Pharma Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Natco Pharma Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Product Portfolio
8.7.5 Natco Pharma Recent Developments
8.8 Hetero
8.8.1 Hetero Comapny Information
8.8.2 Hetero Business Overview
8.8.3 Hetero Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Hetero Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Product Portfolio
8.8.5 Hetero Recent Developments
8.9 Cipla
8.9.1 Cipla Comapny Information
8.9.2 Cipla Business Overview
8.9.3 Cipla Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Cipla Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Product Portfolio
8.9.5 Cipla Recent Developments
8.10 Bristol Myers Squibb
8.10.1 Bristol Myers Squibb Comapny Information
8.10.2 Bristol Myers Squibb Business Overview
8.10.3 Bristol Myers Squibb Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Bristol Myers Squibb Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Product Portfolio
8.10.5 Bristol Myers Squibb Recent Developments
8.11 AbbVie
8.11.1 AbbVie Comapny Information
8.11.2 AbbVie Business Overview
8.11.3 AbbVie Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 AbbVie Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Product Portfolio
8.11.5 AbbVie Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Value Chain Analysis
9.1.1 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Production Mode & Process
9.2 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Distributors
9.2.3 Small Molecules Drugs for Inflammatory Bowel Diseases (IBDs) Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.